Hero-banner

Corporate Profile

Hero-banner

Akero Therapeutics is a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need. Our current focus is on advancing our lead program efruxifermin (EFX) to provide a powerful new treatment for patients with NASH, a disease for which there are currently no marketed therapies.

Corporate Presentation
Corporate Presentation
Download

Share Price

Akero Therapeutics

Dec 1, 2021 3:57 PM EST
Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases from Akero

View All
Nov 26, 2021

Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference

Nov 12, 2021

Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment

Recent Events

View All
Dec 2, 2021 at 3:30 PM EST

4th Annual Evercore ISI HealthCONx Conference

Nov 18, 2021 at 3:00 AM EST

Jefferies London Healthcare Conference

Oct 12, 2021 at 12:00 PM EDT

H.C. Wainwright 5th Annual NASH Investor Conference

Investor Contact

Christina Tartaglia
T: (212) 362-1200
IR@akerotx.com

Media Contact

T: (650) 487-6488
media@akerotx.com


Helpful Tools